Business Wire

GA-INSPIRE-BRANDS

17.1.2024 14:01:31 CET | Business Wire | Press release

Share
Jimmy John’s Announces Global Expansion Plan with Signing of International Franchise Agreements in Canada and Latin America

Today, Inspire Brands announced two international franchise agreements to bring Jimmy John’s, the largest owned-delivery sandwich brand in the United States, to Canada and Latin America, launching the brand’s global expansion plan.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240117651076/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Jimmy John's international store concept design (Photo: Business Wire)

Jimmy John's focus on quality ingredients, convenience and digital innovation blended with ease of operations uniquely positions the brand for international appeal. Its global expansion will usher in a new way for international guests to enjoy its iconic menu—the ability to order hot, toasted sandwiches as a customization option.

"For 40 years, Jimmy John's has taken a straightforward approach to making ridiculously good, quality sandwiches and it's now time to share them with the world," said Michael Haley, President & Managing Director, International for Inspire Brands. “In a global restaurant environment where simplicity is paramount, we're confident this brand is primed for extensive international growth."

Jimmy John’s has reached agreements with two strong operators who both possess significant quick service restaurant experience and have established extensive footprints throughout Canada and Latin America.

  • Foodtastic - A leading franchisor of restaurant brands in Canada, with more than 1,100 restaurants and $1.1 billion in sales.
  • Franquicias Internacionales - Based in El Salvador, has a robust portfolio of several complementary businesses across food and beverage, digital media and logistics.

Jimmy John’s obsessive approach to culinary excellence and operational efficiency has helped fuel its growth in the U.S. and will be the foundation of the brand’s international expansion.

Quality Obsessed:

  • Bread baked fresh in the restaurant throughout the day
  • Premium meats and cheeses, as well as fresh vegetables that are hand-sliced in restaurants daily

Convenience Obsessed:

  • Sandwiches, customized to your liking, made fresh and fast right when you want them
  • Speedy accessibility via drive-thru, pick-up, and delivery

Technology Obsessed:

  • Industry-leading mobile app and online ordering enabled through POS integration
  • Exclusive rewards through the international loyalty program

While Jimmy John's is just embarking on its global journey, Inspire Brands is no stranger to international expansion. As a multi-brand restaurant company with more than 32,000 locations worldwide, including Arby's®, Baskin-Robbins®, Buffalo Wild Wings®, Dunkin'®, Jimmy John's® and SONIC®, Inspire has a robust international presence, with more than 9,900 locations.

Jimmy John's global expansion will be supported by Inspire's extensible, shared services platform and its international team, which has a wealth of experience managing and operating brands globally.

To learn more about growth opportunities with Jimmy John’s and Inspire, please visit inspirebrands.com/franchising/international/.

About Inspire Brands

Inspire Brands is a multi-brand restaurant company whose portfolio includes more than 32,000 Arby’s, Baskin-Robbins, Buffalo Wild Wings, Dunkin’, Jimmy John’s, and SONIC locations worldwide. The company was founded in 2018 and is headquartered in Atlanta, Georgia. For more information, visit InspireBrands.com.

About Jimmy John’s

Jimmy John’s, founded in 1983, is the largest owned delivery sandwich brand in the United States, with more than 2,600 restaurants in 48 states. Jimmy John’s is part of the Inspire Brands family of restaurants. For more information, visit JimmyJohns.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240117651076/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Altasciences Supports 4B Healthcare in Advancing Steroid Nasal Irrigation Rinse to Clinical Trials24.9.2026 14:40:00 CEST | Press release

Altasciences is proud to announce that recent formulation work supporting 4B Healthcare Inc. (“4B”) has helped advance its RhineX nasal irrigation rinse therapy into clinical investigation. Following several months of formulation development, R&D manufacturing, stability testing, and quality assurance support at Altasciences’ CDMO facility in Harleysville, PA, the Tennessee-based pharmaceutical company has received FDA clearance to proceed with clinical testing of RhineX under its IND. First subject dosing is planned for October 2026, approximately seven months after formulation development began. "The concept for RhineX grew out of a problem I have seen in my own ENT practice for years—the need for a better treatment option for allergic rhinitis when conventional medical therapy is not enough,” said Brannon Mangus, MD, Co-Founder and CEO of 4B. “We founded 4B Healthcare to take that physician insight and turn it into a pharmaceutical product that could meaningfully change how these pa

ParaScript Acquired by Stakk to Create a Global Digital Trust Platform Focused on Combating Fraud24.9.2026 14:30:00 CEST | Press release

ParaScript’s AI-powered document intelligence technology integrates with Stakk’s SaaS platform to provide regulated organizations with a stronger defense against AI-driven digital identity fraud.Complementary technologies establish digital trust by continuously assessing identity, documents, behavior and context, making explainable decisions in milliseconds.Combined businesses serve more than 300 enterprise customers and processes more than 110 billion digital interactions annually across the U.S., Europe, the Middle East and Australia. ParaScript, an Al-powered document processing company, today announced that Stakk Limited (ASX: SKK) (“Stakk”), a company publicly traded on the Australian Stock Exchange (ASX), has successfully completed its US$63 million (A$88.7 million) acquisition of ParaScript, LLC and ParaScript Management, Inc. (“ParaScript”), creating a scaled and profitable AI-native digital trust platform. Stakk acquired ParaScript for its industry-leading AI-powered document

SLB Awarded Four Multi-Year Integrated Well Construction Contracts by Aramco24.9.2026 14:04:00 CEST | Press release

Awards expand deployment of SLB's integrated well construction model across Saudi Arabia’s oil and gas reservoirs Global energy technology company SLB (NYSE: SLB) today announced it has been awarded four integrated well construction contracts by Aramco to support oil and gas development across the Kingdom of Saudi Arabia. Under the contracts, SLB will manage end-to-end well construction services, delivering more than 450 wells in the three-year term, with an optional extension of up to two years. "Delivering hundreds of wells across a multi-year program and in multiple operating environments requires an integrated model that connects planning, execution, and digital workflows to set new industry performance benchmarks,” said Steve Gassen, executive vice president of Geographies for SLB. “Awarding SLB these advanced well construction programs at scale reflects Aramco’s confidence in our integrated model and capabilities." SLB's integrated well construction model brings together every as

Sahajanand Medical Technologies Receives EU MDR Certification for Supraflex Cruz and Product Family, Reinforcing Global Compliance and Patient Safety24.9.2026 14:03:00 CEST | Press release

Sahajanand Medical Technologies Limited (SMT), a leading global manufacturer of cardiovascular medical devices, today announced that it has received certification under the European Union Medical Device Regulation (EU MDR 2017/745) for Supraflex Cruz and its product family. SMT is a leading player in India’s drug-eluting stent market and ranks among the top five companies in key European markets, including Germany, Spain and Poland. The certification follows the conformity assessment process established under EU MDR 2017/745 including assessment of SMT’s technical documentation, clinical evaluation and quality management system. Together with SMT’s existing ISO 13485 quality management system and MDSAP certifications, the EU MDR certification confirms that Supraflex Cruz has successfully undergone assessment against the EU MDR’s stringent requirements for safety, performance and clinical evidence. Supraflex Cruz is a sirolimus-eluting coronary stent system designed to improve luminal d

Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)24.9.2026 13:00:00 CEST | Press release

-- Meaningful and consistent efficacy trends across endpoints support continuing with Phase 3 development of 60 mg once daily remlifanserin in ADP, with demonstrated evidence of dose effect-- Narrowly missed primary endpoint of SAPS H+D (p=0.0603) with significance (nominal) on key secondary endpoint of CGI-S-ADP (p=0.0077)-- Favorable safety and tolerability profile across both doses-- Detailed results to be presented at upcoming Clinical Trials on Alzheimer's Disease (CTAD) conference in November-- Conference call and webcast to be held today at 8:00 a.m. Eastern Time Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced Phase 3 enabling topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). For the primary endpoint of change from baseline in the Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye